Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: A cluster-randomized trial

Implementation Science

Volumn 10, Issue 1, 2015, Pages

  Gold, Rachel ^a,b   Nelson, Christine ^b   Cowburn, Stuart ^b   Bunce, Arwen ^a   Hollombe, Celine ^a   Davis, James ^a   Muench, John ^c   Hill, Christian ^d   Mital, Meena ^e   Puro, Jon ^b   Perrin, Nancy ^a   Nichols, Greg ^a   Turner, Ann ^d   Mercer, MaryBeth ^d   Jaworski, Victoria ^e   Howard, Colleen ^b   Abiles, Emma ^b   Shah, Amit ^e   Dudl, James ^f   Chan, Wiley ^f   DeVoe, Jennifer ^b,c   more..

^a CENTER FOR HEALTH RESEARCH   (United States)

^b OCHIN Inc   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Virginia Garcia Memorial Health Center   (United States)

^e Multnomah Department of County Human Services   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Community health centers; Diabetes mellitus; Quality improvement; Translational medical research

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEALTH CARE QUALITY; HEALTH CENTER; HUMAN; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SAFETY NET HOSPITAL; STANDARDS; TOTAL QUALITY MANAGEMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMMUNITY HEALTH CENTERS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; SAFETY-NET PROVIDERS; YOUNG ADULT;

EID: 84931039271     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/s13012-015-0259-4     Document Type: Article

References (50)

1. The White House. The Obama Administration and Community Health Centers. 2012. http://www.whitehouse.gov/sites/default/files/05-01-12_community_health_center_reportpdf; Accessed June 5, 2012.
2. Morgan D. Health centers for poor, uninsured see ranks swell. http://wsau.com/news/articles/2012/may/01/us-health-centers-for-pooruninsured-see-ranksswell/Accessed5/29/15.
3. US DHHS. Community Health Centers and the Affordable Care Act in 2011: Increasing Access to Affordable, Cost Effective, High Quality Care. http://www.bphc.hrsa.gov/about/healthcenterfactsheet.pdfAccessed 5/29/15.
4. Dudl RJ, Wang MC, Wong M, Bellows J. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. Am J Manag Care. 2009;15(10):e88-94.
5. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155-65.
6. Wong W, Jaffe M, Wong M, Dudl RJ. Implementation study-vohs national quality award. Community implementation and translation of kaiser permanente's cardiovascular disease risk-reduction strategy. Perm J. 2011;15(1):36-41. Ref Type: Magazine Article.
7. Pettay HS, Branthaver B, Cristobal K, Wong M. The care management institute: harvesting innovation, maximizing transfer. Perm J. 2005;9(4):37-9.
8. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-16.
10. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25.
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456-62.
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
14. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-41.
15. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. doi:10.1136/bmj.a1840.:a1840.
16. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
17. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62.
18. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136(2):161-72.
19. Antiplatelet Trialists Collaborative. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
20. Klausen K, Borch-Jonsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease an death independent of renal function, hypertension, and diabetes. Circulation. 2004;110:32-5.
21. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713-20.
22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-13.
23. American Diabetes Association. Standards of Medical Care in Diabetes-2008. Diabetes Care. 2008;31(Supp 1):S12-54.
24. Gold R, Muench J, Hill C, Turner A, Mital M, Milano C, et al. Collaborative development of a randomized study to adapt a diabetes quality improvement initiative for federally qualified health centers. J Health Care Poor Underserved. 2012;23(3 Suppl):236-46.
25. Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for specifying and reporting. Implement Sci. 2013;8:139.
26. Baskerville NB, Liddy C, Hogg W. Systematic review and meta-analysis of practice facilitation within primary care settings. Ann Fam Med. 2012;10(1):63-74.
27. Liddy CE, Blazhko V, Dingwall M, Singh J, Hogg WE. Primary care quality improvement from a practice facilitator's perspective. BMC Fam Pract. 2014;15:23.
28. Parchman ML, Noel PH, Culler SD, Lanham HJ, Leykum LK, Romero RL, et al. A randomized trial of practice facilitation to improve the delivery of chronic illness care in primary care: initial and sustained effects. Implement Sci. 2013;8:93.
29. Mold JW, Fox C, Wisniewski A, Lipman PD, Krauss MR, Harris DR, et al. Implementing asthma guidelines using practice facilitation and local learning collaboratives: a randomized controlled trial. Ann Fam Med. 2014;12(3):233-40.
30. Dickinson WP, Dickinson LM, Nutting PA, Emsermann CB, Tutt B, Crabtree BF, et al. Practice facilitation to improve diabetes care in primary care: a report from the EPIC randomized clinical trial. Ann Fam Med. 2014;12(1):8-16.
31. Gold R, Bunce A, Cohen DJ, DeVoe JE, Hollombe C, Nelson C. Reporting on implementation strategies: an example from an intervention adapted across care settings. Ann Fam Med. In press.
32. DeVoe JE, Likumahuwa S, Eiff MP, Nelson CA, Carroll JE, Hill CN, et al. Lessons learned and challenges ahead: report from the OCHIN Safety Net West practice-based research network (PBRN). J Am Board Fam Med. 2012;25(5):560-4.
33. DeVoe JE, Gold R, Spofford M, Chauvie S, Muench J, Turner A, et al. Developing a network of community health centers with a common electronic health record: description of the Safety Net West Practice-based Research Network (SNW-PBRN). J Am Board Fam Med. 2011;24(5):597-604.
34. DeVoe JE, Sears A. The OCHIN community information network: bringing together community health centers, information technology, and data to support a patient-centered medical village. J Am Board Fam Med. 2013;26(3):271-8.
35. Bunce AE, Gold R, Davis JV, McMullen CK, Jaworski V, Mercer M, et al. Ethnographic process evaluation in primary care: explaining the complexity of implementation. BMC Health Serv Res. 2014;14(1):607.
36. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
37. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32 suppl 1:S13-61.
38. Brownson RC, Colditz GA, Proctor EK. Dissemination and implementation research in health: translating science to practice. New York: Oxford University Press; 2012.
39. Massoud MR, Nielson GA, Nolan K, Schall MW, Sevin C. A Framework for Spread: From Local Improvements to System-Wide Change. IHI Innovation Series white paper. Cambridge, MA: Institute for Healthcare Improvement. www IHI org; 2006. Accessed January 8, 2013.
40. Glasgow RE, Vinson C, Chambers D, Khoury MJ, Kaplan RM, Hunter C. National Institutes of Health approaches to dissemination and implementation science: current and future directions. Am J Public Health. 2012;102(7):1274-81.
41. Napoles AM, Santoyo-Olsson J, Stewart AL. Methods for translating evidence-based behavioral interventions for health-disparity communities. Prev Chronic Dis. 2013;10:E193.
42. Albu J, Sohler N, Matti-Orozco B, Sill J, Baxter D, Burke G, et al. Expansion of electronic health record-based screening, prevention, and management of diabetes in New York City. Prev Chronic Dis. 2013;10:E13.
43. Chin MH, Cook S, Drum ML, Jin L, Guillen M, Humikowski CA, et al. Improving diabetes care in midwest community health centers with the health disparities collaborative. Diabetes Care. 2004;27(1):2-8.
44. Nieva VF, Swift E, Fair S. AHRQ Health Care Innovations Exchange report on Scale up and Spread Activities 2011. AHRQ Report, 2011. Rockville, MD: AHRQ; 2011. Ref Type: Report.
45. Rabin BA, Glasgow RE, Kerner JF, Klump MP, Brownson RC. Dissemination and implementation research on community-based cancer prevention: a systematic review. Am J Prev Med. 2010;38(4):443-56.
46. Katz DL, Murimi M, Gonzalez A, Njike V, Green LW. From controlled trial to community adoption: the multisite translational community trial. Am J Public Health. 2011;101(8):e17-27.
47. Kern LM, Ancker JS, Abramson E, Patel V, Dhopeshwarkar RV, Kaushal R. Evaluating health information technology in community-based settings: lessons learned. J Am Med Inform Assoc. 2011;18(6):749-53.
48. James AS, Richardson V, Wang JS, Proctor EK, Colditz GA. Systems intervention to promote colon cancer screening in safety net settings: protocol for a community-based participatory randomized controlled trial. Implement Sci. 2013;8:58.
49. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44(5 Pt 1):1640-61.
50. Institute for Healthcare Improvement. IHI Triple Aim Initiative. http://www.ihi.org/engage/initiatives/TripleAim/Pages/default.aspx.Accessed 5/29/15.